pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Median net price of new drugs jumps 35% from 2022 to 2025, reaching $257,000

Oct 20, 2026·read at STAT ↗Neutral

The Institute for analysis reports that the median net price for 202 newly launched medicines rose 35% between 2022 and 2025 after adjusting for inflation and manufacturer discounts.

The median price increased from $190,000 in 2022 to $257,000 in 2025, underscoring growing cost pressures on new therapies.

The surge adds to ongoing concerns about prescription drug affordability and may shape payer negotiations and pricing strategies across the sector.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more”

read at STAT ↗
688 words · retrieved 21m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: OpenEvidence’s JAMA paper leaves open questionsSTAT
  • 2h agoHow voters feel about trans rights and abortion access will soon be put to the testSTAT
  • 3h agoSTAT+: Dana-Farber, Beth Israel to begin construction of new $1.68 billion cancer hospitalSTAT
  • 5h agoSTAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis findsSTAT
  • 7h agoOpinion: Resident physicians may lose some of their most important work hour protectionsSTAT